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Abstract
A powerful way to separate signal from noise in biology is to convert the molecular data from individual genes or proteins
into an analysis of comparative biological network behaviors. One of the limitations of previous network analyses is that
they do not take into account the combinatorial nature of gene interactions within the network. We report here a new
technique, Differential Rank Conservation (DIRAC), which permits one to assess these combinatorial interactions to quantify
various biological pathways or networks in a comparative sense, and to determine how they change in different individuals
experiencing the same disease process. This approach is based on the relative expression values of participating genes—i.e.,
the ordering of expression within network profiles. DIRAC provides quantitative measures of how network rankings differ
either among networks for a selected phenotype or among phenotypes for a selected network. We examined disease
phenotypes including cancer subtypes and neurological disorders and identified networks that are tightly regulated, as
defined by high conservation of transcript ordering. Interestingly, we observed a strong trend to looser network regulation
in more malignant phenotypes and later stages of disease. At a sample level, DIRAC can detect a change in ranking between
phenotypes for any selected network. Variably expressed networks represent statistically robust differences between
disease states and serve as signatures for accurate molecular classification, validating the information about expression
patterns captured by DIRAC. Importantly, DIRAC can be applied not only to transcriptomic data, but to any ordinal data
type.
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Introduction
Molecular signatures based on the measured abundance of
biomolecules (e.g., mRNA, proteins, metabolites) have the potential
to discriminate among disease subtypes, to predict clinical
outcomes, or to provide insights into the mechanistic underpinnings
of disease progression. Moreover, with sufficient data, these
signatures begin to enable the identification of perturbed networks
that reflect core aspects of the disease process—and thus could
provideinsightsintofunctionallyrelevantdrugtargetsaswellasnew
approaches to diagnostics [1,2]. However, distinguishing signal
from noise in high-throughput data such as mRNA microarray
experiments presents a significant challenge. This noise commonly
results from technical issues in data production and the integration
of datasets from different platforms, laboratories, or even experi-
ments within a lab. Noise in high-throughput data also stems from
biological variability in the sources, such as genetic polymorphisms,
different stages of the biological process, disease stratification, and
stages of disease progression. In the study of human disease
processes, this variability poses a unique hurdle as there are often
only data for a single point in time; when comparing data between
individuals who appear to have the same disease, one doesnotknow
whether theobserved differencesreflect disease subtypes ordifferent
stages of a single disease type.
A fundamental tenant of systems approaches to biology and
medicine is that dynamically changing biological networks mediate
physiological, developmental, and disease processes, and that the
key to understanding these processes is translating network
dynamics into phenotypes. As such, a powerful method to mitigate
some forms of biological noise (hence increasing the utility of high-
throughput data as a diagnostic and scientific tool) is to convert the
molecular data from individual genes or proteins into an analysis
of comparative biological network behaviors. Typically, studies
search for a small number of individual genes whose differential
expression is highly correlated with phenotypic changes. However,
malignant phenotypes in many diseases arise from the net effect of
interactions among multiple genes and other molecular agents
within biological networks. For example, cooperating oncogenes
interact synergistically to evade tumor suppression mechanisms
such as cell-cycle arrest and apoptosis [3,4]. The combinatorial
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complex picture of the underlying biological processes. As such,
the biological insight gleaned from the expression patterns of
individual genes is often limited. Other pitfalls associated with
individual gene expression analysis have been proposed and
discussed elsewhere [2,5,6].
The importance of studying network behavior—evident in most
phenotypes, disease or otherwise—is particularly well-documented
for cancer. Research has linked modulated function on the level of
either metabolic networks [7–9] and/or signaling networks [10–
12] to cancer hallmarks including angiogenesis, increased growth,
metastasis, and evasion of immune detection. Similarly, recent
global genomic analyses in glioblastoma multiforme [13,14] and
pancreatic cancers [15] have revealed both varying numbers and
frequencies of genetic alterations within distinct core networks of
each disease. In light of these findings, microarray data analysis
methods have begun to shift towards identifying biologically
meaningful pathways or networks. We consider all pathways to in
fact be part of interconnected biological networks, and henceforth
use the term network rather than pathway. In general, network
regulation controls the expression levels of related genes
responding to specific conditions. Existing tools for network-based
expression analysis commonly investigate informative patterns of
up-regulation or down-regulation (i.e., increases or decreases in
expression) of genes in different disease states. For example, the
widely-used gene set enrichment analysis (GSEA) platform
identifies networks that are significantly enriched for individual
genes that are highly correlated with a phenotype [5,16]. Other
methods employ a single statistic to represent the collective activity
of a network (e.g., mean or median gene expression) [2,17];
perturbed levels of network activity (i.e., collective up- or down-
regulation) are then examined to identify those networks most
differentially expressed between phenotypes. These frameworks
have been applied to diverse cancer systems and serve as a robust
source of biological discovery [2,18].
Studying cellular regulation of networks in terms of ‘‘unidirection-
al’’ changes may, however, overlook subtle, yet influential, changes in
the relationships among the genes within a network. This drawback
directly reflects the combinatorial operation of genes in networks, in
which the actions of one gene greatly influences the actions of other
genes. By accounting for these combinatorial interactions we can
begin to alleviate the signal-to-noise issues in disease-perturbed
networks (as well as dynamically changing networks mediating
physiology or development). In particular, even the elementary
interactions captured by the relative orderings among two or three
genes have been shown to provide powerful biomarkers for
separating phenotypes [19–21]. With methods that aim to identify
statistically significant up- or down-regulation of genes or networks,
results will also depend largely on the context of the microarray
experiment. Cellular regulation in a case with a number of up- or
down-regulated genes in one phenotype versus another manifests as
an increase in absolute expression levels above some threshold,
relative to all other genes on the microarray. Even when thresholds
are tuned to produce statistically significant results, the findings are
still based on indirect measurements, (i.e., fluorescence) and therefore
may depend heavily on the experimental set up, type of data
normalization, and other factors. In addition to the technical
limitations of microarray experiments, biological context can greatly
impact results. For instance, if nearly all genes are differentially
expressed between two phenotypes, then no single network will be
statistically ‘‘enriched’’ for change. It is also possible that neither
individual network genes nor any network as a whole will display
notable over- or under-expression in response to environmental or
disease-related stimuli. The importance of accounting for combina-
torial gene interactions—and to do so without need to reference all of
the genes on the microarray—again becomes clear.
We have developed a new method called Differential Rank
Conservation (DIRAC) which considers combinatorial behavior,
and provides quantitative measures of how network expression
differs within and between phenotypes. The DIRAC approach
assesses cellular regulation of a network in the context of the relative
levels of expression for participating genes. For each microarray, the
expression values of the network genes are ordered from highest
expression (ranked first) to lowest expression (ranked last); regulation
is then quantified entirely by the rankings of genes within a selected
network. Consequently, DIRAC identifies and measures network-
level perturbations from a completely novel perspective, namely the
‘‘combinatorial comparisons’’ of network genes as opposed to
increases or decreases alone, allowing one to study how this ordering
changes in different conditions—and thus begin to infer the
consequences of combinatorial gene interactions. As a result, this
approach has two key advantages over tools that measure absolute
changes in expression levels. First, it accounts for gene-gene
interactions; second, the results do not depend on the other genes
on the microarray or on the method of normalization used. These
are both critical pointsindealingwith signal-to-noiseissues.Notably,
as DIRAC treats each network independently, it can still identify
perturbed networks even when every gene on the microarray is
differentially expressed (in contrast to enrichment measures).
Our strategy for representing network rankings uses pairwise
comparisons of gene expression levels. Such pairwise comparisons
can yield two-gene predictors with simple decision rules for
classification of expression profiles [22,23]. These decision rules
have in turn resulted in highly accurate two-gene diagnostic
classifiers based on relative expression reversals that have proven
effective for molecular identification of cancer [19–23]. We extend
the relative expression reversal concept to networks. However,
analyzing sample-to-sample changes for every possible distinct
ordering of gene expression values within a network is not
computationally feasible; there are simply too many possible
orderings, i.e., permutations. Knowing the states of all pairwise
Author Summary
The systems approach to medicine derives from the idea
that diseased cells arise from one or more perturbed
biological networks due to the net effect of interactions
among multiple molecular agents; by measuring differ-
ences in the abundance of biomolecules (e.g., mRNA,
proteins, metabolites) we can identify reporters of network
states and uncover molecular signatures of disease.
However, a major limitation of previously published
network analyses is the focus on small numbers of
individual, differentially-expressed genes, hence the failure
to take into account combinatorial interactions. We report
a new technique, Differential Rank Conservation, for
identifying and measuring network-level perturbations.
Our rank conservation index is based entirely on the
relative levels of expression for participating genes and
allows us to detect differences in network orderings
between networks for a given phenotype and between
phenotypes for a given network. In examining cancer
subtypes and neurological disorders, we identified net-
works that are tightly and loosely regulated, as defined by
the level of conservation of transcript ordering, and
observed a strong trend to looser network regulation in
more malignant phenotypes and later stages of disease.
We also demonstrate that variably expressed networks
represent robust differences between disease states.
Differential Rank Conservation (DIRAC)
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motivates our representation. For each distinct pair of genes
within a network, we consider a binary variable indicating whether
or not the mRNA abundance of the first gene is less than that of
the second gene; in fact, we restrict attention to the probability of
this event within a phenotype for each pair of genes. In this way,
we avoid the combinatorial complexity of permutations and
represent the ‘‘expected’’ ordering of network genes for a given
phenotype as a binary template. Unlike the probabilities of full
orderings, pairwise frequencies are reliably estimated with typical
sample sizes, while still capturing a great deal of information about
network regulation. We subsequently compute a matching score to
signify how closely each sample’s network ordering matches a
phenotype-specific template.
We can use DIRAC at the population level to quantify
conservation differences between networks for a given phenotype.
Specifically, DIRAC allows us to use rankings to identify and
contrast tightly and loosely regulated network types of a single
phenotype:
i. a network is considered tightly regulated within its phenotype if
the ranks of network genes are mostly unchanged among
samples;
ii. a network is considered loosely regulated if the ranks of network
genes are greatly varied between samples of the same
phenotype.
Tightness of regulation for a selected network is best understood
as the allowed variation in gene expression levels observed across
the population. This offers an advantage over studying up- or
down-regulation only because it indicates the level of control
across samples in a population. In this work we use the DIRAC
approach to identify networks that are tightly regulated in a
number of human cancers and neurological disorders. Since
networks under tight control in a particular phenotype may be
necessary to maintain a specific cellular function, tightly regulated
networks that change across phenotypes may provide insight into
processes such as disease progression.
Additionally, DIRAC can be applied at the sample level to
identify conservation differences between phenotypes for a
specified network. At this level the DIRAC method can identify
variably expressed networks that reveal statistically robust
differences between disease states, leading to highly accurate
classification of expression profiles from various diseases. When
used to separate expression profiles, the DIRAC method is
noteworthy because it (i) is independent of microarray data
normalization; (ii) results in a simple yet efficient classifier for
phenotype distinction; and (iii) appears to be comparable in
accuracy to state-of-the-art classification methods. Learning the
regulation of gene rankings within different states allows us to
discover molecular signatures composed of related genes that
distinguish phenotypes, identify networks most involved in disease
transitions, and assist identification of potential therapeutic targets.
Importantly, while we focus on gene expression in the present
study, the method can be generalized to any ordinal dataset, and
thus can be applied to such biological data types as proteomics,
gene copy number, chromosomal position, and so forth.
Results/Discussion
Overview of DIRAC Methods
The DIRAC approach was used to evaluate regulation of gene
ordering within networks in different diseases. For each micro-
array sample in each phenotype studied, we characterized the
ordering of network genes (i.e., network ranking) in terms of
comparisons between the expression values of pairs of genes.
Based on the comparison statistics, we defined a rank template for
each network and phenotype representing the expected (i.e., most
common) pairwise ordering of gene expression for that network in
that phenotype. We employed a simple measure—a rank matching
score (R)—to determine how well the network ranking in each
individual sample (i.e., expression profile) matched the ordering
defined in the rank template. Averaging R over all samples within
a phenotype yields a network-specific rank conservation index (mR)
which represents how well, on average, all samples in the same
phenotype match the corresponding rank template. Alternatively,
comparing two rank matching scores for the same sample leads to
a highly-discriminating rank difference score (D) that allows one to
determine the most variably expressed networks between two
phenotypes. The calculation of these quantities is illustrated in
Figure 1.
Several prototypical scenarios arise from these measures. In one
scenario (Figure 2, left), conservation indices are used to
measure the consistency with which network rankings are
maintained in a population, and are used to identify tightly
regulated networks in each phenotype. One situation, where all
samples have similar network rankings, yields a large rank
conservation index and indicates the network is tightly regulated.
A second situation, where the ordering of network genes is highly
varied, yields a small rank conservation index and indicates the
network is loosely regulated. In a second prototypical scenario, the
DIRAC method detects changes in ranking (i.e., shuffling of gene
expression values) between phenotypes for a selected network
(Figure 2, right). The top networks selected by DIRAC based on
the difference score can be used to classify gene expression profiles
by phenotype.
We first applied DIRAC to investigate network rankings using
gene expression profiles obtained from patients with different
stages of prostate disease. The gene expression data, originally
reported by Yu et al. [24] and publically available in the NCBI
Gene Expression Omnibus (GDS2545), contains 108 human
prostate samples: 18 samples of normal prostate tissue (NP) from
organ donors, 65 primary prostate tumor (PT) samples, and 25
metastatic prostate tumor (MT) samples. The findings for normal
prostate and prostate cancer samples presented below represent
the main features of the DIRAC method, and can be similarly
obtained for any disease expression data.
In addition to the more detailed prostate cancer analysis, we
examined a number of other disease phenotypes including cancer
subtypes and neurological disorders, and identified both tightly
regulated and variably expressed networks in each. For each
dataset, we grouped expression levels of genes into 248 human
signaling networks, defined according to the BioCarta gene sets
collection in the Molecular Signatures Database (MSigDB) [5]. In
order to ensure that the networks examined were as complete as
possible, we used gene synonym information from NCBI to
replace unmatched names in each dataset with those belonging to
networks in the BioCarta collection. This step led to an average
increase of 5% in the fraction of network genes (1296 total across
248 networks) for which a corresponding expression value was
found (Table S1).
Population-Level DIRAC
The population-level analysis is centered on the rank conser-
vation index (mR)-defined for each network and each phenotype.
This index represents the degree of conservation in the rankings of
the expression levels of the network genes, averaged over samples
of the phenotype.
Differential Rank Conservation (DIRAC)
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doi:10.1371/journal.pcbi.1000792.g001
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cancerous prostate. For a given phenotype, the extent of
gene ranking conservation within networks will vary across
networks. The ten most tightly regulated networks in normal
prostate (NP), primary prostate tumors (PT), and metastatic
prostate tumors (MT), as measured by rank conservation indices,
are shown in Table 1. Large rank conservation index values
indicate similar gene orderings among all samples of each
phenotype in these networks, and hence tight regulation. This
suggests that the combinatorial gene interactions in each network
are quite similar among different patients.
Identifying networks that are tightly regulated in some
phenotypes and loosely regulated in others suggests that the level
of control across samples in a population may change dramati-
cally, reflecting the nature of the disease process. While identifying
changes in tightness of regulation of networks can provide insight
into molecular differences between phenotypes, some networks
may be tightly regulated in all phenotypes examined. For example,
we found that the G-protein signaling (GS) network is the most
tightly regulated network in normal prostate (NP), as well as in
primary (PT) and metastatic prostate tumors (MT). The GS
network comprises major signaling proteins downstream of G-
protein coupled receptors, including both the catalytic (PRKACA)
and regulatory (PRKAR1A) subunits of the cAMP-dependent
protein kinase C (PKC). PKC family members phosphorylate a
wide variety of protein targets and are known to be involved in
diverse cellular signaling networks, such as those associated with
cell adhesion, cell transformation, cell cycle checkpoint, and cell
volume control. In 18 NP samples, the pairwise orderings among
the six GS network genes matched the corresponding normal
prostate rank template identically for all 15 pairs in the network
(mR=1.000). Similarly, network rankings in PT samples and MT
samples matched the respective templates for 98.9% (mR=0.989)
and 99.5% (mR=0.995) of all pairwise orderings on average. We
also found that a single network ranking was shared by the
majority of NP samples (100%), PT samples (83%), and MT
samples (92%); in particular, therefore, the GS network rank
template was identical in all three phenotypes. Furthermore, the
remaining samples in PT and in MT displayed only a single
mismatch in pairwise orderings compared to the template.
There are several possible explanations for observing tight
regulation of certain network rankings in a phenotype. In the
simplest case, the genes in a network may be expressed at greatly
disparate magnitudes, making a change in their relative expression
rankings less likely. We can see that this is most likely true for the
GS and FOSB networks, both of which displayed the highest rank
conservation for all three prostate phenotypes. The average gene-
to-gene expression variance across all samples for these networks
fell between 1.14–1.58, roughly three times the average gene-to-
gene variance for all 248 networks (,0.41). As such, a change in
the relative ordering among genes in these networks would require
a more dramatic change in the expression of individual genes.
Networks like GS and FOSB are therefore analogous to
‘‘housekeeping’’ genes, as the ranking of genes in each is expected
to remain the same in most samples.
Alternatively, small variation in ordering—nearly the same
ranking in all samples of the same phenotype—could indicate that
a network is critical to maintaining some specific cellular function.
This is more likely in cases with less gene-to-gene expression
variance within a network; if pairwise orderings can be easily
altered by small changes in expression but remain consistent, some
force such as selective pressure might drive the cell to minimize
fluctuation in the expression of network genes. We found that the
SET network is tightly regulated in NP samples, but displays much
smaller gene-to-gene variance than networks like GS and FOSB.
The SET network—also known as the granzyme mediated
apoptosis pathway—comprises a total of 11 genes (illustrated in
Figure 3), and is an important cytotoxic T cells mechanism for
fighting tumors and virus-infected cells [25]. While the SET
network displays greater variation in ranking among NP samples
than GS or FOSB (mR=0. 945), 16 out of 18 samples show only
five or fewer mismatches compared to the 55 pairs in the rank
template. We hypothesize that expression of genes within the SET
network is highly consistent in NP samples to maintain proper
function of cellular defense mechanisms.
Tightly regulated networks in disease phenotypes might also
lead to useful hypotheses about cell behavior. The RAN network,
similar to SET, is tightly regulated across MT samples, and shows
relatively low gene-to-gene variation within the network. The
RAN network contains five genes: regulator of chromosome
Figure 2. Prototypical scenarios observed for networks in DIRAC.
doi:10.1371/journal.pcbi.1000792.g002
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binding proteins 1 and 2 (RANBP1 and RANBP2), and RAN
GTPase activating protein 1 (RANGAP1). In MT samples, on
average, the pairwise orderings among the five RAN network
genes matched the corresponding MT rank template for 96.0% of
all pairs in the network (mR=0.960). This network is involved in
the export of mRNA transcripts from the nucleus to the cytosol for
subsequent translation. Although it is unclear what advantage tight
regulation of the RAN network may confer upon metastatic
prostate tumors, there is clearly little variation in network ranking.
Importantly, the mutation rates in cancer cells are increased 200-
400 fold—providing ample opportunity for changes to be fixed by
natural selection or random fixation (if the change is not selectively
advantageous or disadvantageous).
We can learn more by examining the tightness of regulation for
the same network in different phenotypes. The SET network in
PT samples has a rank conservation index equal to 0.909, which is
significantly lower than in NP samples (P-value,0.05); similarly,
mR for SET in MT samples is equal to 0.891. As seen in Figure 3,
the decreased network rank conservation in PT and MT is due to
a greater number of samples with rankings different from the
respective templates (i.e., more samples with greater numbers of
mismatches). The increased variation in network ranking seen in
the two stages of prostate cancer might indicate that the biological
Table 1. Most tightly regulated networks in normal prostate and primary and metastatic prostate tumors, as indicated by rank
conservation index values.
Tightly regulated networks in NP
Network name Num. genes Num. gene pairs
a Avg. variance in NP mR in NP
GS 6 15 1.328 1.000
FOSB 4 6 1.141 0.981
AKAP13 7 21 0.796 0.955
AGPCR 11 55 0.811 0.955
RNA 8 28 0.453 0.948
CACAM 12 66 0.551 0.947
NDKDYNAMIN 17 136 0.619 0.946
ETC 8 28 0.350 0.946
SET 11 55 0.537 0.945
SKP2E2F 10 45 0.339 0.943
Tightly regulated networks in PT
Network name Num. genes Num. gene pairs Avg. variance in PT mR in PT
GS 6 15 1.270 0.989
FOSB 4 6 1.525 0.979
AKAP13 7 21 0.880 0.960
ARGININEC 6 15 0.548 0.960
PLK3 8 28 0.672 0.951
CDC42RAC 15 105 0.547 0.946
RNA 8 28 0.489 0.946
CREM 7 21 0.563 0.944
BOTULIN 4 6 0.850 0.944
AGPCR 11 55 0.771 0.943
Tightly regulated networks in MT
Network name Num. genes Num. gene pairs Avg. variance in MT mR in MT
GS 6 15 1.322 0.995
FOSB 4 6 1.575 0.980
CREM 7 21 0.659 0.966
S1P 6 15 0.465 0.963
RAN 5 10 0.371 0.960
SLRP 4 6 1.227 0.960
BOTULIN 4 6 0.722 0.953
AKAP13 7 21 0.787 0.947
SARS 10 45 0.819 0.939
RAB 10 45 0.441 0.937
aThe number of gene pairs is equal to Gm(Gm–1)/2, where Gm is the number of genes in the network.
doi:10.1371/journal.pcbi.1000792.t001
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apoptosis) plays a lesser role in behavior of these cells, and is
therefore under looser control. It is also possible that in primary
and metastatic prostate tumors—obviously more malignant
phenotypes compared to normal prostate—the SET network
becomes deregulated and that this deregulation contributes to its
malignancy. Alternatively, an increase in mutation rates with
malignancy might have resulted in more random fixations.
These rank conservation indices estimate population statistics
based on limited sample sizes (on the order of 20–100, as seen in
Figure 3. Example of a tightly regulated network in normal prostate. A simplified diagram of the SET network, comprising 11 signaling
proteins involved in granzyme mediated apoptosis, is shown in the center. The NP rank template for the network is highlighted yellow, and each
unique ranking observed in NP samples is shown to the right with mismatches highlighted red. The histograms at the bottom demonstrate the
increased variation in ranking in PT and MT, indicated by greater number of mismatches from the respective rank templates.
doi:10.1371/journal.pcbi.1000792.g003
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indices were the same. For instance, the difference in the rank
conservation index for the SET network between NP and PT or
between NP and MT could be a small-sample effect and would
need to be validated with either a larger study or by a suitable
permutation test (see Section II below). However, even these
small-sample estimates generate specific hypotheses, such as an
increase in disorder in the more malignant phenotype, which can
then be meaningfully explored by examining a variety of datasets
and phenotypes—discussed in the following sections.
Deregulation of network ranking in disease. As described
for the SET network above, certain networks may be tightly
regulated in one phenotype, but not in another. The SET network
appears to be relatively tightly regulated in normal prostate, but
more loosely regulated in both primary and metastatic prostate
tumors. Cases such as this represent the deregulation of a network
in one phenotype relative to another. We used the difference in
rank conservation index values between phenotypes as the basis
for identifying the most deregulated networks. For example, in
comparing NP samples to MT samples, we first calculated the rank
conservation index for all networks in both phenotypes. Next, we
identified the networks with the greatest absolute difference in
index values between NP and PT (i.e., highly conserved in one
class but not in the other). Based on sample permutation tests, we
found that 67 out of 248 networks had a significant difference in
index values (P-value,0.05; see Materials and Methods). The
network with the largest conservation difference—the
FIBRINOLYSIS network—was more tightly regulated in NP
(mR=0.891) than in MT (mR=0.736) (Table 3). The
FIBRINOLYSIS network comprises 12 genes and breaks down
fibrin clots formed during coagulation. It has previously been
reported that patients with metastatic prostate cancer occasionally
exhibit enhanced fibrinolytic activities with symptoms of bleeding,
epistaxis, or other forms of hemorrhage [33]. Deregulation of the
FIBRINOLYSIS in MT samples might therefore be directly linked
to malignant features of the disease. However, without further
information it is impossible to discern whether loose regulation of
this network is a causative mechanism in MT, or occurs as a
downstream effect of some other perturbation in tumor
progression.
Upon inspecting the remaining differentially regulated networks
between NP and MT, we found that in fact, 57 out of 67
significantly deregulated networks identified showed tighter
regulation in NP than in MT (Figure 4J). The strong majority
of networks more tightly regulated in the NP (P-val-
ue=5.14610
28 from a binomial distribution; see Table 4) lends
evidence to the theory that deregulation of network ranking is in
some way related to increased malignancy. As such, the DIRAC
Table 2. Human disease gene expression datasets studied with DIRAC.
Dataset Ref Samples Tissue type Disease/source (subtypes)
a Short name
b Subtype samples
A [19] 68 gastrointestinal sarcoma gastrointestinal stromal tumor GIST 37
Leiomyosarcoma LMS 31
B [26] 43 ovarian tumors carcinoma-like ovarian tumor CL ovarian tumor 20
adenoma-like ovarian tumor AL ovarian tumor 23
C [27] 101 skin fibroblasts Marfan syndrome subjects MFS fibroblast 60
control subjects non-MFS fibroblast 41
D [28] 44 head and neck skin cells head and neck squamous cell carcinoma HNSCC 22
normal head and neck skin cells normal head/neck 22
E [29] 60 primary breast
cancer tumor
patients non-response
(cancer recurred) to treatment
(nr) breast cancer 28
patients responsive
(disease-free) to treatment
(r) breast cancer 32
F [30] 61 dorsolateral prefontal
cortex and orbitofrontal
cortex
Bipolar disorder patients bipolar cortex 30
control patients non-bipolar cortex 31
G [31] 72 blood and bone marrow acute myeloid leukemia AML 1 25
acute lymphocytic leukemia ALL 1 47
H [32] 48 blood and bone marrow acute myeloid leukemia AML 2 24
acute lymphocytic leukemia ALL 2 24
I [24] 83 normal and tumorgenic
prostate
primary prostate tumors (p) prostate cancer 65
normal prostate tissue normal prostate 18
J [24] 43 normal and metastatic
prostate
metastatic prostate tumors (m) prostate cancer 25
normal prostate tissue normal prostate 18
K [24] 90 prostate tumor metastatic prostate tumors (m) prostate cancer 25
primary prostate tumors (p) prostate cancer 65
aFor each set of expression profiles, the two subtypes are listed in order from most to least malignant (e.g., tumor type with worst prognosis or cancer versus control).
bShort names are used to reference specific phenotypes in subsequent figures.
doi:10.1371/journal.pcbi.1000792.t002
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in assessment of the progression of disease. To explore this
hypothesis further, we examined a number of gene expression
datasets available for public download from the NCBI Gene
Expression Omnibus (Table 2). These datasets included expres-
sion profiles from multiple cancers such as breast, ovarian, and
blood (leukemia), as well as diseases of the brain/nervous system,
skin, and intestinal tract (note: the leukemia datasets G and H were
excluded from this particular comparison, as we found no clear
evidence for which subtype—AML or ALL—is more malignant).
We repeated the procedure described for NP and MT for each
binary phenotype comparison from the expression data. In all but
one case out of nine, the less malignant phenotype had a greater
number of high conserved (tightly regulated) networks (Figure 4).
That is, a network appears much more likely to become
deregulated in worse cases of disease. Importantly, the dataset
for the one exception—comparing Marfan syndrome and normal
fibroblasts—contained expression values for only ,4,000 genes
(compared to 20,000 or more in most of the other datasets). Due to
the small number of genes, many of the networks contained
significant gaps, which may have produced less robust results. Still,
the overall trend seen in Figure 4 suggests that in malignant
phenotypes, networks are often more loosely regulated, with
greater variation in expression ranking of participating genes from
Table 3. Most differentially regulated networks between three stages of prostate disease.
Differentially regulated networks (PT vs. NP)
Network name Num. genes Num. gene pairs
a mR in PT mR in NP Abs. difference in mR P-value
TCRA 12 66 0.859 0.928 0.069 5.85E-04
TCRMOLECULE 5 10 0.871 0.939 0.068 6.69E-04
EIF2 7 21 0.854 0.915 0.061 1.33E-03
TERC 6 15 0.877 0.933 0.056 2.29E-03
NEUTROPHIL 8 28 0.848 0.901 0.053 3.33E-03
GLYCOLYSIS 8 28 0.879 0.929 0.050 4.57E-03
ACE2 11 55 0.835 0.885 0.050 4.72E-03
FIBRINOLYSIS 12 66 0.847 0.891 0.044 9.17E-03
INTRINSIC 22 231 0.852 0.896 0.044 9.45E-03
CLASSIC 10 45 0.886 0.930 0.044 9.74E-03
Differentially regulated networks (MT vs. NP)
Network name Num. genes Num. gene pairs ı `R in MT ı `R in NP Abs. difference in ı `R P-value
FIBRINOLYSIS 12 66 0.736 0.891 0.156 26.66E-16
EXTRINSIC 12 66 0.716 0.870 0.155 26.66E-16
INTRINSIC 22 231 0.761 0.896 0.135 2.02E-05
CLASSIC 10 45 0.829 0.930 0.100 2.90E-04
TERC 6 15 0.843 0.933 0.091 6.21E-04
ION 5 10 0.892 0.806 0.086 8.35E-04
COMP 14 91 0.832 0.914 0.082 1.20E-03
NEUTROPHIL 8 28 0.819 0.901 0.082 1.21E-03
ARF 15 105 0.829 0.911 0.081 1.32E-03
PEPI 5 10 0.808 0.889 0.081 1.34E-03
Differentially regulated networks (MT vs. PT)
Network name Num. genes Num. gene pairs mR in MT mR in PT Abs. difference in mR P-value
EXTRINSIC 12 66 0.716 0.856 0.140 26.66E-16
FIBRINOLYSIS 12 66 0.736 0.847 0.111 8.06E-06
INTRINSIC 22 231 0.761 0.852 0.091 4.03E-05
ION 5 10 0.892 0.803 0.089 6.05E-05
PEPI 5 10 0.808 0.895 0.087 6.85E-05
ARGININEC 6 15 0.880 0.960 0.080 1.65E-04
LEPTIN 8 28 0.807 0.727 0.080 1.73E-04
NOTCH 4 6 0.853 0.931 0.077 2.42E-04
PLC 8 28 0.800 0.859 0.059 1.74E-03
BETAOXIDATION 6 15 0.864 0.922 0.058 1.86E-03
aThe number of gene pairs is equal to Gm(Gm–1)/2, where Gm is the number of genes in the network.
doi:10.1371/journal.pcbi.1000792.t003
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malignancy highlights the utility of studying gene expression
ordering within networks, and also reveals a striking phenomenon
that could drive future investigation and may lead to new
understandings of gene expression in disease.
Global regulation of networks across phenotypes. Aver-
aging rank conservation indices over all the networks provides a
measure of global regulation of networks in different phenotypes.
For example, networks in normal prostate are more highly
conserved on average (0.903) than networks in metastatic prostate
cancer (0.884). This difference suggests that the more malignant
cancer subtype (MT) may have greater overall variation in
network rankings among different samples. We used the gene
expression datasets described above to compare global regulation
Figure 4. Deregulation of networks in disease. For each dataset, networks were selected according to the greatest absolute difference in rank
conservation between the two phenotypes. Using this subset of networks, the rank conservation index values in the less malignant phenotype (y-
axis) were plotted against indices in the more malignant phenotype (x-axis). Higher rank conservation in the less or more malignant phenotypes is
indicated by points above or below the diagonal line, respectively. Panel labels (A–K) correspond to datasets listed in Table 2.
doi:10.1371/journal.pcbi.1000792.g004
Table 4. Statistical significance of network deregulation in malignant phenotypes.
Dataset # tighter in less malignant # tighter in more malignant Outcome Binomial P-value
A 26 0 1 0.00
B 122 1 1 0.00
C 13 18 0 0.76
D 23 6 1 0.00
E 13 1 1 6.10E-05
F 9 7 1 0.23
I 24 6 1 1.62E-04
J 57 10 1 3.41E-10
K 39 13 1 6.38E-05
Total 326 62 8 0.00
Binomial P-value for outcomes: 0.002
doi:10.1371/journal.pcbi.1000792.t004
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phenotype, we calculated rank conservation indices for all
networks and used the average conservation as a rough measure
of how tightly or loosely regulated networks tend to be in each case.
We used the average index value to order phenotypes from
highest to lowest global conservation. Phenotypes with the highest
average conservation primarily have tightly regulated networks
across samples in the population. For example, most networks in
non-bipolar cortex and bipolar cortex were found to have
conservation index values greater than 0.95 (seen as bright colors
on the heatmap in Figure 5) for average values of 0.9561 and
0.9556, respectively. In contrast, many networks in the two breast
cancer phenotypes (r—responsive to treatment; nr—non-respon-
sive to treatment) have rank conservation indexes less than 0.80
(dark colors on the Figure 5 heatmap). In this case, the low global
conservation—average index values of 0.835 and 0.826 in (r)
breast cancer and (nr) breast cancer, respectively—suggests that
network rankings in these disease phenotypes have looser
regulation and greater variation. Based on a one-way ANOVA,
the estimated overall P-value for the ordering of phenotypes in
Figure 5 is zero.
Interestingly, the trend of lower conservation in more malignant
phenotypes described in the previous section seems to persist even
from a coarser, global perspective. For example, networks in the
less malignant adenoma-like ovarian tumors are more highly
conserved on average (0.947) than in more malignant carcinoma-
like ovarian tumors (0.913). The same was seen when examining
all three prostate phenotypes, where normal prostate is more
tightly regulated overall than primary (p) prostate cancer, which
itself is more tightly regulated than metastatic (m) prostate cancer.
Even for the most highly conserved phenotypes (non-bipolar and
bipolar cortex) and lowest conserved phenotypes (breast cancers),
Figure 5. Diverse rank conservation of networks across phenotypes. Colors on the heatmap represent rank conservation indices for each
network in 19 different phenotypes, where brightest indicates very tight regulation of network ranking in a phenotype and darkest indicates loose
regulation of networks, with greater shuffling of gene rankings.
doi:10.1371/journal.pcbi.1000792.g005
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malignant phenotype of each pair. We also observed interesting
differences observed based on tissue-type, where expression
ranking of networks in brain and ovarian tissue displayed higher
conservation on average than prostate tissue, which is in turn is
more highly conserved than in blood and in breast tissue. Thus, at
least two global trends must be considered in evaluating network
deregulation: (i) the severity of the disease, and (ii) the tissue of
origin.
Sample-Level DIRAC
In order to identify variably expressed networks between two
selected phenotypes, we designed a rank difference score (D),
calculated for each sample based on rank matching scores. For a
particular network, this measure indicates the similarity between
the ordering of network genes in a sample to the template of one
class versus the template of the other. The difference score ranges
from -1 to 1, with positive values suggesting the first phenotype,
and negative values suggesting the second, culminating in simple
rules for classifying an expression profile. Our purpose in
introducing the rank difference score was two-fold: (i) to identify
variably expressed networks between two selected phenotypes; and
(ii) to validate the DIRAC approach to network identification, and
the emphasis on combinatorial interactions, by demonstrating the
discriminative power of the networks identified.
Variably expressed networks in normal prosate and
cancerous prostate. As shown in Figure 6, the positive
versus negative trend holds for most samples in MT and NP across
all networks. To determine the most variably expressed networks
between MT and NP, we (i) defined rank templates for each
phenotype; (ii) calculated rank matching scores and evaluated the
rank difference score for each sample; and (iii) chose the networks
with the largest estimated classification rate. Specifically, the
classification rate for a network is defined as the average of
sensitivity and specificity for predicting sample classes in the
training data (i.e., apparent accuracy).
To evaluate whether variably expressed networks represented
meaningful differences between MT and NP gene expression
profiles, we used permutation-based testing to assess the statistical
significance of estimated network classification rates (see Mate-
rials and Methods). A total of 176 networks significantly
discriminated between expression profiles of MT and NP (P-
value,0.05), the top ten of which appear in Table 5. Among
these differentially expressed networks, we estimated that only
6.7% (between 11 and 12 of the 176 total) are likely to have been
found by chance rather than based on true differences between the
phenotypes, as determined by the FDR.
The principal features governing the rank difference score, and
also an example of its application to molecular classification, are
illustrated in Figure 7 for the MAPK network, which we
identified as one of the most differentially expressed networks
between normal prostate and metastatic prostate tumors. Here,
R(xn) denotes the rank matching score for a profile xn, and
superscripts indicate the network and phenotype of the rank
template (e.g., R
(MAPK,MT)(xn) represents the rank matching score
for a sample when compared to the ordering defined in the MT
template). The rank difference score is the difference in matching
score values for a particular sample: R
(MAPK,MT)(xn)–
R
(MAPK,NP)(xn). This measure captures low variance of network
ranking within phenotypes, but disparate rankings between
phenotypes. The rank difference values calculated for the MAPK
network for all samples are shown in Figure 7, along with the
corresponding phenotype predictions (i.e., MT where positive, NP
if negative). Interestingly, MAPK signaling has been previously
reported to be involved in the cancerous transformation of
prostate cells [34,35].
DIRAC-based classification of disease phenotypes. The
top networks selected by DIRAC based on the difference score
(i.e., the single best network for separating each different pair of
phenotypes) were used to classify gene expression profiles in cross-
validation. Specifically, we used leave-one-out cross-validation
(LOOCV) to estimate how accurately the top networks selected
could predict the phenotype of future samples (Figure 8).
Importantly, all processes including defining rank templates,
calculating rank difference scores, and selecting the best network
were done within cross-validation, using only the training samples
(i.e., no information from test samples was used to train classifiers).
For comparison, we selected the top Gm differentially expressed
genes—where Gm is equal to the number of genes in the top
network selected by DIRAC—and used the top-scoring pair (TSP)
algorithm [22,36] and support vector machines (SVM) [37,38] to
classify samples in each of the datasets. We found that our method
performed well in a number of the datasets, with estimated
accuracies between 92–96% in gastrointestinal sarcoma, ovarian
cancer, leukemia, and prostate cancer—including comparisons
between normal prostate and cancer as well as different stages of
prostate cancer (Figure 8). In cases with poor accuracies, such as
responsiveness of breast cancer to therapy, bipolar disorder, and
Marfan syndrome, we observed that other methods also failed to
accurately classify samples, suggesting that these phenotypes are
inherently difficult to separate based on the available expression
data.
Overall, we found that classification, when restricted to only the
genes in the top network (as determined by DIRAC), is nearly as
accurate as using the overall Gm most differentially expressed genes
(in TSP or SVM). Our foremost goal was not to propose a new
classifier, but to aid in biological discovery and hypothesis
generation; the classification accuracy simply affirms the robust-
Figure 6. Differential rank conservation across all networks for
a set of two prostate phenotypes. Positive rank difference scores
predict a metastatic sample and negative difference scores predict a
sample as normal.
doi:10.1371/journal.pcbi.1000792.g006
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classification experiment validates DIRAC by demonstrating the
importance of combinatorial interactions: the potential loss of
discriminating power in individual genes is countered by
discriminating interactions.
Implications for Systems Medicine
Systems medicine approaches assume that disease arises from
disease-perturbed biological networks in the relevant organ or
organs. These disease-perturbed networks alter the envelopes of
information that they express—and these changes encode the
pathophysiology of the disease. Moreover, the altered patterns of
information can elucidate new strategies for diagnosis or therapy.
Future drugs will likely be designed to re-engineer disease-
perturbed networks to behave in a more normal fashion, or at
least to abrogate their most deleterious consequences. This will
require a new drug target identification approach, and re-
engineering disease-perturbed networks appropriately will almost
always require multiple drugs. Likewise, the perturbed nodal
points in disease-perturbed networks can be expressed as proteins
in the blood—where the disease-altered levels of expression may
reflect the disease process. These disease-altered blood proteins
will create unique blood fingerprints specific for each disease
process, and thus provide powerful diagnostics. These advances
Table 5. Most variably expressed networks between different stages of prostate cancer.
Variably expressed networks (PT vs. NP)
Network name Num. genes Num. gene pairs
a Template difference
b Apparent accuracy P-value
KERATINOCYTE 46 1035 0.070 0.981 ,1.0E-07
TOLL 31 465 0.073 0.945 1.21E-05
MAPK 83 3403 0.064 0.941 2.02E-05
MET 35 595 0.103 0.941 2.02E-05
FCER1 36 630 0.059 0.931 6.85E-05
INTEGRIN 34 561 0.094 0.923 1.21E-04
AT1R 34 561 0.096 0.922 1.25E-04
ERK 29 406 0.037 0.921 1.29E-04
CARDIACEGF 17 136 0.118 0.920 1.33E-04
IL1R 28 378 0.071 0.915 1.81E-04
Variably expressed networks (MT vs. NP)
Network name Num. genes Num. gene pairs Template difference Apparent accuracy P-value
MAPK 83 3403 0.111 1.000 ,1.0E-07
DEATH 29 406 0.128 1.000 ,1.0E-07
IL2RB 35 595 0.096 1.000 ,1.0E-07
HIVNEF 53 1378 0.148 1.000 ,1.0E-07
MET 35 595 0.165 1.000 ,1.0E-07
NO1 27 351 0.125 1.000 ,1.0E-07
NFAT 47 1081 0.164 1.000 ,1.0E-07
PPARA 50 1225 0.100 1.000 ,1.0E-07
ACTINY 19 171 0.123 1.000 ,1.0E-07
FCER1 36 630 0.111 0.990 ,1.0E-07
Variably expressed networks (MT vs. PT)
Network name Num. genes Num. gene pairs Template difference Apparent accuracy P-value
FCER1 36 630 0.119 0.985 ,1.0E-07
TCR 44 946 0.103 0.969 ,1.0E-07
BCR 33 528 0.133 0.969 ,1.0E-07
HIVNEF 53 1378 0.119 0.969 ,1.0E-07
MET 35 595 0.126 0.969 ,1.0E-07
PDGF 27 351 0.128 0.957 ,1.0E-07
BIOPEPTIDES 37 666 0.107 0.957 ,1.0E-07
MAPK 83 3403 0.100 0.954 ,1.0E-07
IL2RB 35 595 0.087 0.954 ,1.0E-07
AT1R 34 561 0.111 0.954 ,1.0E-07
aThe number of gene pairs is equal to Gm(Gm–1)/2, where Gm is the number of genes in the network.
bThe template difference represents the Hamming distance between two binary rank template vectors.
doi:10.1371/journal.pcbi.1000792.t005
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To date, most of the evaluation of networks has employed lists of
transcripts that are perturbed from the levels of their counterparts
in normal organs. This listing, as with genome-wide association
(GWAS) studies, misses the key fact that disease-perturbed
networks must be assessed in the context of the combinatorial
interactions of their nodal components.
Our method is the first approach that begins to account for the
combinatorial behavior of interacting genes, mRNAs and/or
proteins. Using DIRAC-based calculations allows us to begin to
assess the key disease-perturbed networks that may aid in the
approach to diagnosis and therapy. We also stress that these
methods will almost certainly prove powerful in the stratification of
disease types. The example of gastrointestinal stromal tumors
(GIST) and leiomyosarcomas (LMS), histologically indistinguish-
able, but clearly classifiable by a primitive version of DIRAC, is
striking. We believe this will be a powerful approach in, for
example, distinguishing various types of neurodegenerative
diseases, as well as the stratification of complex diseases such as
Alzheimer’s. Notably exciting, some of the key transcripts used in
this classification process actually encoded proteins secreted into
the blood. Findings of this nature could lead to the use of altered
blood levels of proteins for diagnosis without the need to sample
disease tissues. Emerging technologies will make these measure-
ments possible at the single cell level, exposing other exciting
possibilities for diagnosis using the strategies outline above. We
predict the application of DIRAC as a powerful clinical tool in the
advancing proactive, rather than reactive, new medicine—the so-
called P4 medicine (predictive, personalized, preventive and
participatory)—where blood and single-cell diagnostics will be
the foundation of the P4-medicine revolution.
Conclusions
In this study we demonstrate a novel method to identify highly
discriminative biological networks based on differing patterns of
gene expression ranking within networks. These results provide a
coarse, but meaningful, glimpse into patterns of network
regulation for different phenotypes based on combinatorial
relationships between the involved genes. For example, when
comparing two disease states, it appears to be very common
(although not universal) for network rankings to be more varied—
or less tightly regulated—in the more pathological state. This
increased disorder associated with malignancy might be expected,
as mutations and other altered behavior of biomolecules lead to
breakdown of typical functioning in biological networks; rank
conservation index values calculated in DIRAC represent a
quantitative means to study and further verify this notion.
Importantly, this method not only identifies perturbed networks,
but does so in such a way that it can classify samples. Thus,
predictive accuracy becomes a strong measure for the validity of
Figure 7. Differential rank conservation of the MAPK network in metastatic prostate cancer and normal prostate. (A) Histograms of
rank matching scores. MT template matching scores (R
(MAPK,MT)) are higher on average in MT samples than NP matching scores (R
(MAPK,NP)). In NP
samples, R
(MAPK,NP) scores are higher on average than R
(MAPK,MT) scores. (B) Rank matching scores for the MAPK network. Comparing the two rank
matching scores in each sample, MT samples are more similar to the MT template than to the NP template in all cases; NP samples are ranked more
similarly to the NP template more than the MT template in all cases. (C) Rank difference score values for the MAPK networks. Samples are classified as
MT if the rank difference score is greater than zero and as NP if the difference is less than zero.
doi:10.1371/journal.pcbi.1000792.g007
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phenotype. Such high predictive accuracy in classification adds
much stronger evidence that biologically meaningful network
differences are found than only a low P-value or FDR, which
simply measure how likely the result derives from chance.
Measures of global regulation can also give useful information for
designing research to identify expression-based classifiers of
disease. For instance, it would be more fruitful to search for
clear molecular signatures with tightly regulated phenotypes. In
cases with mostly loosely regulated networks, the greater variation
from sample-to-sample would pose a more difficult challenge for
identifying reliable classifiers. Studying rank regulation of
biologically relevant networks thus offers a promising tool for
measuring network behavior within and across different popula-
tions. Looking forward, the results obtained through this
approach should provide increased insight into phenotypic
processes of importance in biology and medicine.
Materials and Methods
The methods and analyses presented here were performed
entirely in Matlab. Source code files are available for download at
http://www.igb.uiuc.edu/labs/price/downloads.
Microarray Data
Given the list {g1,… ,gGm}o fGm genes within a network m on a
microarray, we let X=(X1,… ,XGm) denote the corresponding
expression profile, where Xi is the expression level of gene gi. Our
data then consists of a Gm x N matrix; the n
th column represents the
expression profile xn of the n
th sample, n=1, …, N. In addition,
each sample is labeled by a phenotype YM{A, B, …, K}. The
labeled training set is F={(x1,y 1), …, (xN,y N)}. Expression
profiles X and phenotype labels Y are regarded as random
variables, and the elements of F represent independent and
identically distributed samples from some underlying probability
distribution of (X, Y).
Our analysis is based entirely on the ranks within each
expression profile. With Gm genes, there are Gm! possible orderings
for the expression values. The networks we consider typically have
tens or hundreds of genes; consequently, working directly with
individual permutations is not feasible. For example, any estimated
distribution over permutations using training data would be highly
singular. Instead, we base the analysis entirely on pairwise
comparisons.
Rank Template Matching for Networks
Knowing the ordering of the gene expressions within each
network expression profile is equivalent to knowing all of the
pairwise orderings, i.e., whether Xi,Xj or Xi.Xj for each distinct
pair of genes 1#i, j#Gm within the network m. Evidently, there are
Gm(Gm–1)/2 such pairs. For example, if there are Gm=4 genes,
then there are six distinct ordered pairs: {(1, 2), (1, 3), (1, 4), (2, 3),
(2, 4), (3; 4)}. In order to define a template representing the
expected ranking of network genes within a phenotype, we
consider the probabilities Pr(Xi,Xj |Y=k) for each pair of genes
gi,gj and for each phenotype k. We estimate these probabilities
from the training set by computing the fraction of samples in each
phenotype for which gene gi is expressed less than gene gj. The
rank template for a fixed network m and phenotype k is the binary
vector T
(m,k) of length Gm(Gm–1)/2 where the i,j
th component is 1 if
Pr(Xi,Xj |Y=k).0.5 and 0 if Pr(Xi,Xj |Y=k)#0.5. The
calculation of a rank template is illustrated in Figure 1.
Given an expression profile xn for the network m, there is then a
natural measure for how well the sample matches the template
T
(m,k). The rank matching score of sample n is denoted by R
(m,k)(xn)
and is defined to be the fraction of the Gm(Gm–1)/2 pairs for which
the observed ordering within xn matches the template—the
orderings expected for phenotype k. See Figure 1 for an
illustration of a rank matching score.
Rank Conservation Indices
Averaging the rank matching score over all the samples in a
phenotype k yields a rank conservation index denoted by
mR
(m,k)=E(R
(m,k)|Y=k). This index is estimated by averaging the
scores R
(m,k)(x) over all the samples (x, y) in the training set for
which y=k. Whereas the rank matching score is a sample-based
statistic, i.e., it is defined for each expression profile, the rank
conservation index is a population statistic. The rank conservation
index can be seen as a measure of the stability in rankings among
the network genes in the phenotype. Two extreme cases
correspond to (i) pure random shuffling of the expression values
in the phenotype from sample to sample, in which case
mR
(m,k)<0.5; and (ii) all samples displaying exactly the same
ordering, in which case mR
(m,k)<1. In general, there are many gene
pairs gi and gj which are expressed on different scales, and hence
xi,xj across nearly all samples and phenotypes. As a result, one
generally finds mR
(m,k)&0.5. This index is similar to entropy in the
sense that values of mR
(m,k)%1 indicate a highly disorganized state
Figure 8. Classification with DIRAC compared to other
methods.
doi:10.1371/journal.pcbi.1000792.g008
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phenotype k from sample to sample and values of mR
(m,k)<1
indicate a highly ordered state in which samples have very similar,
and hence predictable, orderings among the genes.
Rank Difference Scores
Consider two phenotypes Y=A, B, and a fixed network m.I f
network m is tightly regulated in one phenotype, the samples from
that phenotype, say Y=A, will have high R
(m,A) values on average.
But if mR
(m,k) is large for both k=A and k=B, and if the two rank
templates T
(m,A) and T
(m,B) are significantly different, then the
samples from phenotype Y=A will generally have low values for
the statistic R
(m,B) as well as high values for the statistic R
(m,A), and
vice-versa for the samples from phenotype Y=B. We capture this
phenomenon, namely low variance of network ranking within a
phenotype, but high variance between phenotypes, with a single
statistic calculated for each sample: the difference
D
(m)(xn)=R
(m,A)(xn)–R
(m,B)(xn). Clearly, –1#D
(m)(xn)#1 with positive
(respectively, negative) values providing evidence that the
phenotype of sample n is Y=A (resp., Y=B). As a result, the
difference score provides a classifier for phenotype identification
based on the degree of regulation of the genes in network m. A new
sample n is predicted to belong to phenotype Y=A if D
(m)(xn).0
and to phenotype Y=B if D
(m)(xn)#0. The classification rate for
network m is then: g(m)=Pr(D
(m)(X).0|Y=A)*Pr(Y=A)+Pr(D
(m)
(X)#0|Y=B)*Pr(Y=B). The calculation of a rank difference score
was shown in Figure 1.
For example, if Y=A denotes prostate cancer and Y=B denotes
normal prostate, and if we assume that the two phenotypes are a
priori equally likely, then g(m) is simply the average of sensitivity
and specificity relative to identifying cancer. In order to determine
the most variably expressed networks between two given
phenotypes, we calculate rank templates for each phenotype,
evaluate the differential score for each sample in the training set
and choose the networks with the largest estimated classification
rate.
One previously reported method, k-TSP, classifies expression
profiles based on k pairs of genes with the most significant
expression reversals among all assayed genes [22]. The classifier
based on the rank difference score is also based on k pairs of genes,
with k equal to the distance between the two rank templates. To
see this, notice that upon computing the difference D
(m)(xn) for
pathway m and phenotypes A and B, the gene pairs (i,j) for which
T
(m,A)(i,j)=T
(m,B)(i,j) cancel out. The DIRAC-based classifier
therefore reduces to voting among the gene pairs whose
probabilities straddle 0.5—i.e., satisfy Pr(Xi,Xj |Y=A),0.5,
Pr(Xi,Xj |Y=B) or vice versa. However, these k pairs of genes are
those in the ‘‘top-scoring network’’ as determined by DIRAC
rather than the most discriminating k pairs overall (as would be
identified by k-TSP).
Significance Testing
Procedures for estimating statistical significance are described
below for metastatic prostate tumors (MT) and normal prostate
(NP). Identical procedures were used for all binary phenotype
datasets studied.
Deregulated networks based on the difference in rank
conservation indices. Under the null hypothesis that no
systematic difference in gene expression profiles exists between
MT and NP, (i) the original phenotype labels were randomly re-
assigned to samples, and rank conservation indices were calculated
for all networks in each phenotype; (ii) the absolute difference in
rank conservation index values between the two phenotypes was
calculated for each network (i.e., h(m)=|mR
(m,MT)–mR
(m,NP)| for the
m
th network); (iii) the first two steps were repeated for 1,000
permutations to generate a null distribution of rank conservation
difference values; and (iv) the significance level for h(m)
representing deregulation of a network between MT and NP
was measured as the probability of observing differences in rank
conservation greater than or equal to h(m) in the null distribution.
Classification rate for networks based on the rank
difference score. Under the null hypothesis that no
systematic difference in gene expression profiles exists between
MT and NP, (i) the original phenotype labels were randomly re-
assigned to samples, and rank difference scores were calculated for
each sample in all networks; (ii) sample classes in the permuted
dataset were predicted as MT or NP based on whether the
difference score was positive or negative, respectively, and scores
were assigned to each network as measured by the estimated
classification accuracy (i.e., g(m) for the m
th network); (iii) the first
two steps were repeated for 10,000 permutations to generate a null
distribution of network classification rates; and (iv) the significance
level for the g(m) in predicting MT and NP profiles was measured
as the probability of observing classification rates greater than or
equal to g(m) in the null distribution. To address the issue of
multiple-hypothesis testing, we also estimated the false discovery
rate (FDR) for each significance level, representing the fraction of
our selected features which we would expect to be false positives.
Evaluating Classification Performance
We used leave-one-out cross validation to estimate the
(generalization) error rate of each classification method studied.
Importantly, for each classification method tested, all processes
were done using only the training samples without including any
information from the test sample. Within each iteration of the
cross validation loop, expression profiles in the original training
data F={(x1,y 1), …, (xN,y N)} are divided into two groups: a
training set (Ftrain) and a test set (Ftest). The classifier is trained on
the N–1 samples of Ftrain and then used to predict the phenotype of
the remaining ‘‘left out’’ sample in Ftest. The overall cross
validation classification rate after N total train-test divisions and
predictions is calculated as the average of sensitivity and specificity.
Details for training and testing with each type of classifier are
described below.
DIRAC. Rank templates, rank matching scores, and rank
difference scores are calculated uniquely for each new instance of
the training set Ftrain. The single best network is chosen based on
the classification rate for samples of Ftrain, and the rank templates
for this network are then used to assign two rank matching scores
to the remaining sample comprising Ftest. If the difference in
matching scores is positive, the sample is predicted to be of
phenotype A, otherwise it is classified as phenotype B.
TSP. The top-scoring pair (TSP) algorithm is described in
detail elsewhere [22]. Here, we first filtered the total number of
transcripts in Ftrain, keeping only the top Gm most differentially
expressed genes (DEGs), where Gm is equal to the number of genes
in the best network selected by DIRAC. The top features (i.e.,
DEGs) were selected based on the Wilcoxon ranksum test.
Searching among all possible pairwise combinations of genes in
the reduced dataset, we identified a single best pair (Xi and Xj) for
which the difference |Pr(Xi,Xj | A)–Pr(Xi,Xj | B)| is maximized
(or alternatively, |Pr(Xi.Xj | A)–Pr(Xi.Xj | B). The phenotype of
Ftest is then predicted by comparing the expression levels for this
gene pair.
SVM. Prior to training a support vector machine (SVM)
classifier on the samples of Ftrain, we also filtered down to the top
Gm DEGs within each cross validation loop, where Gm is equal to
the number of genes in the best network selected by DIRAC. The
Differential Rank Conservation (DIRAC)
PLoS Computational Biology | www.ploscompbiol.org 16 May 2010 | Volume 6 | Issue 5 | e1000792SVM was then trained on the expression values of these Gm genes
using a Gaussian kernel, and then used to predict the phenotype of
Ftest.
Supporting Information
Table S1 Increasing network completeness with NCBI gene
name information.
Found at: doi:10.1371/journal.pcbi.1000792.s001 (0.01 MB PDF)
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